BioSpace News Archive

Global Genes and Child Neurology Foundation Outline “Guiding Principles of Rare Disease Care and Patient Access” in Joint Report, Urging Health System Stakeholders to Help Protect Patients

Havn Life Sciences Inc. is pleased to announce that it has filed and obtained a receipt from the securities regulatory authorities in British Columbia, Alberta, Saskatchewan and Ontario for its final non-offering long form prospectus dated September 3, 2020

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced it was granted U.S. Patent No. 10,760,052 on September 1, 2020. These patent claims are directed to inhibiting a TLR4-mediated immune response though use of one or more unique filamin A binding molecules. Cassava Sciences’ lead drug candidate, sumifilam, is a novel molecule. The Company’s patent protection in the area

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that it will host a two-part virtual miniseries in September focused on key topics related to omidubicel , an advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of a bone marrow transplant. The webcasts will take

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to study investigational treatments for pa

PhotoniCare, Inc., a company dedicated to revolutionizing healthcare by providing physicians with better diagnostic tools, announced an oversubscribed $5.2 million Series A financing led by i2E Management Company Inc., with co-investment from OSF Ventures, Sony Innovation Fund, and Dreampact Ventures.

Anthem, Inc. (NYSE: ANTM) has named Jeffrey D. Alter Executive Vice President, IngenioRx and Anthem Health Solutions, effective September 8, 2020. Mr. Alter will serve as a member of the company’s Senior Leadership Team and report directly to Gail K. Boudreaux, President and Chief Executive Officer, Anthem. “Jeff is a respect

New study has important patient safety implications, as shortening dialysis timeline reduces reliance on riskier vascular access procedures

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, today announced that management will participate in the following virtual healthcare investor conferences: Citi’s 15th Annual BioPharma Virtual Conference on Thursday, September 10, 2020. H.C. Wainwright 22nd A

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression, and other central nervous system (CNS) disorders,